FDA Approves Givlaari (givosiran) for Acute Hepatic Porphyria

Article Link: FDA Approves Givlaari (givosiran) for Acute Hepatic Porphyria

CAMBRIDGE, Mass.–(BUSINESS WIRE) November 20, 2019 –Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) approved Givlaari (givosiran) injection for…

Source: FDA New Drug Approvals